Our aim is to transform the fundamental understanding of human biology into effective treatments. We do this by setting up collaborations between Amsterdam Neuroscience and external stakeholders with assets (i.e. small molecules, biologics, or ATMPs) in the field neurology and psychiatry.
Translational research facilitates the characterization of disease processes, generates and validates novel hypotheses based on direct human observation, and allows for collaboration between principal investigators of Amsterdam Neuroscience and medical chemistry experts in companies outside our campus.
Here we cross the gap between industrial R&D and the clinical development. The Industry Alliance Office facilitates this by initiating, facilitating and structuring the scientific discussions leading to clearly defined project plans and research contracts.
As illustrated here, Amsterdam Neuroscience has integrated its work with industrial drug development pipelines, by working with teams of principal investigators coming from various disciplines. In this way, we enable a meaningful ‘carry-over’ of
the latest insights from the bench, where curiosity driven research is performed, to the bedside, where purpose driven or clinical research is performed.
Vice versa, unresolved issues in diagnostics, target engagement of (immuno-) therapies, brain imaging, and the efficacy and side effects of novel therapies are communicated back to the innovation teams, to basic research experts but also to students, residents, technicians and business developers.